RxSight, Inc. (RXST) Misses Q2 EPS by 10c, provides guidance

RxSight, Inc. (NASDAQ: RXST) reported Q2 EPS of ($0.29), $0.10 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $33.6 million versus the consensus estimate of $38.55 million.

GUIDANCE:

RxSight, Inc. sees FY2025 revenue of $120-130 million, versus the consensus of $151.1 million.

Gross margin in the range of 72% to 74%, representing an implied increase of 130 basis points to 330 basis points compared to 2024;
Operating expenses in the range of $145.0 million to $155.0 million, representing an implied increase of 7% to 14% compared to 2024; and
Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.

For earnings history and earnings-related data on RxSight, Inc. (RXST) click here.

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Sonoco (SON) Tops Q2 EPS by 2c; offers guidance
• Bernstein SocGen Group Upgrades Sona BLW Precision (SONACOMS:IN) to Outperform